1258 Changing perceptions of oncologists referring advanced colorectal (ACRC) patients (pts) to phase 1 trials: an evidence based approach

André T. Brunetto; D.S.W. Tan; David Olmos; Tami Yap; Sophia Frentzas; Shahneen Sandhu; Katie Ann Denholm; Bee Ayite; Johann S. de Bono; S.B. Kaye

doi:10.1016/s1359-6349(09)70470-7

Back

1258 Changing perceptions of oncologists referring advanced colorectal (ACRC) patients (pts) to phase 1 trials: an evidence based approach

Article 2009 en

Related publications

Article2008

Phase 1 trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors

Emily K. Bergsland, Andrew H. Ko, Margaret A. Tempero, Kerry S. Whittaker, Tim Frederik Weber, Lily Fong, J. W. Park, Benjamin M. Yeh, Douglas Hanahan, Alan P. Venook

Article1998

AN EVIDENCE-BASED APPROACH TO ROUND TABLES AND CONSENSUS CONFERENCES

Jean Louis Vincent, Jacques Berré

Article2013

12‐minute consultation: an evidence‐based approach to the management of dysphagia

Ali Al‐Hussaini, E.H. Latif, Vijay Singh

Clinical Otolaryngology

Article2017

Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).

Masafumi Ikeda, Kenji Ikeda, Masatoshi Kudo, Yukio Osaki, Takuji Okusaka, Toshiyuki Tamai, Takuya Suzuki, Takashi Hisai, Hideaki Miyagishi, Kiwamu Okita, Hiromitsu Kumada

Article2016

Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study

Ignacio Melero, Bruno Sangro, Thomas Yau, Chih‐Hung Hsu, Masatoshi Kudo, Todd S. Crocenzi, T.-Y. Kim, Su Pin Choo, Jörg Trojan, Tim Meyer, T.H. Welling, Winnie Yeo, Arun Chopra, Jeffrey Anderson, C.l.a. De Cruz, L. Láng, Jaclyn Neely, Anthony B. El-Khoueiry

1258 Changing perceptions of oncologists referring advanced colorectal (ACRC) patients (pts) to phase 1 trials: an evidence based approach

Discussion(0)

Related publications

Phase 1 trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors

AN EVIDENCE-BASED APPROACH TO ROUND TABLES AND CONSENSUS CONFERENCES

12‐minute consultation: an evidence‐based approach to the management of dysphagia

Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).

Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study